Leukemia therapy has evolved from general chemotherapy to highly specific "targeted" medications that attack the unique biology of cancer cells.

🔬 Medication Classes

Leukemia drugs generally fall into four main categories. Each works through a fundamentally different mechanism. Understanding how your medication works can help you feel more informed and engaged in your treatment plan.

💥

Cytotoxic Chemotherapy

The oldest and most established class of anti-cancer drugs. Cytotoxic chemotherapy works by disrupting DNA replication — the process cells use to copy their genetic material before dividing. Because leukemia cells divide much faster than most normal cells, they are more vulnerable to these drugs. However, chemotherapy also affects other fast-dividing healthy cells (hair, gut lining, bone marrow), which causes many of the well-known side effects.

How It Works

These drugs interfere with DNA synthesis, damage the DNA double helix, or block enzymes needed for cell division. The result: cancer cells cannot replicate and undergo programmed cell death (apoptosis).

Key Drugs in This Class

Cytarabine (Ara-C)

A nucleoside analog that tricks cancer cells during DNA synthesis. The backbone of the 7+3 regimen for AML.

Daunorubicin / Idarubicin

Anthracycline antibiotics that intercalate into DNA and inhibit topoisomerase II, preventing DNA unwinding.

Fludarabine

A purine analog used in CLL and as part of FLAG-IDA or transplant conditioning regimens.

Common Side Effects: Nausea, hair loss, mouth sores, low blood counts (neutropenia, anemia, thrombocytopenia), increased infection risk, fatigue. Most side effects are temporary and resolve after treatment ends.

🎯

Targeted Therapy

A revolution in cancer treatment. Targeted therapies are designed to block specific proteins or pathways that cancer cells depend on to grow and survive. Unlike chemotherapy, they largely spare normal cells, resulting in fewer side effects. However, they only work if your leukemia cells carry the specific molecular target — this is why genetic/molecular profiling at diagnosis is so critical.

How It Works

Think of a targeted drug as a key designed for one specific lock. It binds to a mutant protein on or inside the cancer cell, blocking the signals that tell the cell to divide or survive. Normal cells that don't have this mutation are mostly unaffected.

Key Drugs in This Class

Venetoclax (Venclexta)

A BCL-2 inhibitor. BCL-2 is a protein that helps cancer cells avoid death. Venetoclax removes this protection, triggering apoptosis. Used in AML (with HMA) and CLL.

Midostaurin (Rydapt) / Gilteritinib (Xospata)

FLT3 inhibitors. The FLT3 mutation drives aggressive cell growth — these drugs block the mutant FLT3 signal. Midostaurin for newly diagnosed; Gilteritinib for relapsed AML.

Ivosidenib / Enasidenib

IDH1/IDH2 inhibitors. These mutations block cell maturation. The inhibitors restore normal cell differentiation, allowing immature blasts to mature into functional cells.

TKIs (Imatinib, Dasatinib, Ponatinib)

Tyrosine Kinase Inhibitors for CML. They block the BCR-ABL fusion protein created by the Philadelphia chromosome — transforming CML from fatal to a manageable chronic condition.

Why Molecular Testing Matters: Your doctor will test your leukemia cells for specific mutations (FLT3, IDH1/2, NPM1, BCR-ABL, etc.) to determine which targeted therapies may help you. Without the matching mutation, these drugs are ineffective.

🧬

Hypomethylating Agents (HMAs)

These are epigenetic therapies — they don't damage DNA directly but instead change how genes are read. In leukemia cells, important tumor-suppressor genes are often silenced by excess methyl groups attached to the DNA (a process called hypermethylation). HMAs remove these chemical tags, effectively "turning back on" the genes that help cells mature and die normally. They are often preferred for older patients or those who cannot tolerate intensive chemotherapy.

How It Works

Imagine genes as light switches that have been glued in the "off" position by methyl groups. HMAs dissolve the glue, allowing the switches to flip back on. The re-activated genes instruct the cell to mature or self-destruct, restoring normal blood cell production.

Key Drugs in This Class

Azacitidine (Vidaza)

Given as a subcutaneous injection, typically on a 7-day cycle every 28 days. The standard HMA for MDS and AML. Often paired with Venetoclax for a powerful combination.

Decitabine (Dacogen)

An IV infusion given over a 5-day cycle. Works through same mechanism as Azacitidine. An oral version (ASTX727 / Inqovi) combines Decitabine with Cedazuridine for at-home dosing.

What to Expect: HMA therapy is generally outpatient — you visit the clinic for your injections and go home the same day. You may need monthly cycles for 4-6 months before seeing full response. Many patients continue HMA therapy indefinitely as maintenance.

🛡️

Immunotherapy

Rather than attacking cancer cells directly, immunotherapy empowers your own immune system to recognize and destroy them. Cancer cells often evade immune detection by hiding or mimicking normal cells. Immunotherapy drugs can strip away this disguise, flag cancer cells for destruction, or directly connect immune cells to cancer cells like a biological bridge. This category includes antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR-T therapy.

How It Works

Immunotherapies use engineered antibodies or modified cells. Some carry toxic payloads directly to cancer cells (ADCs). Others physically link a T-cell to a cancer cell (BiTEs), forcing the immune cell to attack. CAR-T goes further by permanently engineering T-cells (see our Treatments page for details).

Key Drugs in This Class

Gemtuzumab Ozogamicin (Mylotarg)

An antibody-drug conjugate (ADC) targeting CD33 on AML cells. The antibody delivers a cell-killing toxin directly inside the cancer cell.

Blinatumomab (Blincyto)

A BiTE antibody for B-cell ALL. It simultaneously binds a T-cell and a cancer cell, creating a physical bridge that triggers immune-mediated killing.

Ibrutinib (Imbruvica)

A BTK inhibitor for CLL that blocks signaling in malignant B-cells. Transforms CLL treatment by allowing long-term oral therapy without traditional chemotherapy.

The Future: Immunotherapy is the fastest-growing area of leukemia research. New BiTE antibodies, CAR-T products, and checkpoint inhibitors are in clinical trials. Ask your doctor aboutclinical trial options.

Common Drugs & Their Roles

🎗️ Lymphoma-Specific Medications

Lymphomas are treated with a distinct set of targeted agents, antibody-drug conjugates (ADCs), and bispecific antibodies. Many of these drugs are specific to lymphoma biology and are separate from the leukemia medications covered above.